The Prevalence of Hypercortisolism in Patients with Type 2 Diabetes and Microvascular Complications: A Prospective Observational Case-Control Study
, 2, 3, 4, 5, 6
Abstract
Objective: The goal of this study was to examine the prevalence of hypercortisolism in patients with type 2 diabetes (T2D), and the association of cortisol with microvascular complications. Materials and methods: This prospective observational case-control, single-center study included 107 patients with T2D. After evaluating their microvascular complications, the patients were divided into 2 groups. Group 1 consisted of 57 patients with complications, and group 2 consisted of 50 patients without. Serum 08h cortisol and adrenocorticotropic hormone (ACTH), 09h cortisol after a short dexamethasone test (DEX cortisol), traditional risk factors, and lipid and inflammatory profiles were determined and correlated among the 2 groups. Results: Prevalence of hypercortisolism in patients with T2D was 6.3%, in patients with complications it was 10.5%, and 2.0% in patients without complications. In group 1 we found higher basal cortisol and ACTH, and higher low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) levels when compared to group 2 (p < 0.05). A more positive correlation of cortisol with CRP was found in group 1 compared to group 2 (rho = 0.255, p = 0.011). We did not find a significant difference in sex, body mass index (BMI), treatment modality, diabetes duration, triglyceride, or fibrinogen levels among the groups. Conclusions: Higher serum cortisol levels and higher prevalence of hypercortisolism were significantly associated with diabetic microvascular complications. Systemic inflammation indicators positively correlated with cortisol levels and microvascular complications. This suggests a potential connection between cortisol, inflammation, and microvascular complications in T2D. Further research is needed to clarify the causality of this
relationship.
Keywords: type 2 diabetesmicrovascular complicationcortisoldexamethasoneinflammation
References
- WHO Mortality Database (online database). Geneva: World Health Organization. http://apps.who.int/healthinfo/statistics/mortality/causeofdeath_query/ (15.06.2024).
- Yau JWY, Rogers SL, Kawasaki R, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35(3): 556–564.
- Bora A, Balasubramanian S, Babenko B, et al. Predicting the risk of developing diabetic retinopathy using deep learning. Lancet Digit Health. 2021; 3(1): e10–e19.
- Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep. 2013; 13(6): 814–823.
- Jaiswal M, Divers J, Dabelea D, et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care. 2017; 40(9): 1226–1232.
- de Boer IH, Sibley SD, Kestenbaum B, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol. 2007; 18(1): 235–243.
- Chiodini I, Adda G, Scillitani A, et al. Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care. 2007; 30(1): 83–88.
- Ceriello A, Prattichizzo F. Variability of risk factors and diabetes complications. Cardiovasc Diabetol. 2021; 20(1): 101.
- Chiodini I, Torlontano M, Scillitani A, et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol. 2005; 153(6): 837–844.
- Brunner EJ, Hemingway H, Walker BR, et al. Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation. 2002; 106(21): 2659–2665.
- Navaneethan SD, Zoungas S, Caramori ML, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102(5S): S1–S127.
- Sherlock M, Scarsbrook A, Abbas A, et al. Adrenal Incidentaloma. Endocr Rev. 2020; 41(6): 775–820.
- Kebebew E. Adrenal Incidentaloma. N Engl J Med. 2021; 384(16): 1542–1551.
- Catargi B, Rigalleau V, Poussin A, et al. Occult Cushing's syndrome in type-2 diabetes. J Clin Endocrinol Metab. 2003; 88(12): 5808–5813.
- Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023; 189(1): G1–G42.
- Favero V, Cremaschi A, Parazzoli C, et al. Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside. Int J Mol Sci. 2022; 23(2).
- Aresta C, Soranna D, Giovanelli L, et al. When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. Endocr Pract. 2021; 27(12): 1216–1224.
- Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(1): 136–154.
- American Diabetes Association. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2021; 44(Suppl 1): S15–S33.
- Collins AJ, Foley RN, Gilbertson DT, et al. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl (2011). 2015; 5(1): 2–7.
- Hoogeveen E. The Epidemiology of Diabetic Kidney Disease. Kidney and Dialysis. 2022; 2(3): 433–442.
- Chang Ni, Ying G, Wei L, et al. Correlation between serum cortisol and chronic complications in patients with type 2 diabetes mellitus. Journal of New Medicine. 2021; 52(4): 260–264.
- Shamshirgaran SM, Mamaghanian A, Aliasgarzadeh A, et al. Age differences in diabetes-related complications and glycemic control. BMC Endocr Disord. 2017; 17(1): 25.
- Karimi MA, Vaezi A, Ansari A, et al. Lipid variability and risk of microvascular complications in patients with diabetes: a systematic review and meta-analysis. BMC Endocr Disord. 2024; 24(1): 4.
- Thorand B, Löwel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med. 2003; 163(1): 93–99.
- Amasi-Hartoonian N, Sforzini L, Cattaneo A, et al. Cause or consequence? Understanding the role of cortisol in the increased inflammation observed in depression. Curr Opin Endocr Metab Res. 2022; 24: 100356.
- Johar H, Spieler D, Bidlingmaier M, et al. Chronic Inflammation Mediates the Association between Cortisol and Hyperglycemia: Findings from the Cross-Sectional Population-Based KORA Age Study. J Clin Med. 2021; 10(13).